Female patients with diffuse large B-cell lymphoma (DLBCL) have worse outcomes when receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the morning.
MONDAY, Feb. 6, 2023 (HealthDay News) Female patients with diffuse large B-cell lymphoma (DLBCL) have worse outcomes when receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in the morning, according to a study published online Dec. 13 in JCI Insight. Dae Wook Kim, from KAIST in Daejeon, South Korea, and colleagues performed a
Latest Articles freerepublic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freerepublic.com Daily Mail and Mail on Sunday newspapers.
Latest Articles freerepublic.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freerepublic.com Daily Mail and Mail on Sunday newspapers.